Three RNAi, miRNA Firms Record Strong Gains in Stock Value Since the End of 2008
April 30, 2009
Three RNAi, miRNA Firms Record Strong Gains in Stock Value Since the End of 2008
The companies — Rosetta Genomics, MDRNA, and Tekmira Pharmaceuticals — have all seen their shares more than double since Dec. 31, significantly outperforming the Nasdaq Biotechnology Index.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Grants Prometheus Rights to Sell Suite of microRNA Diagnostics in US
April 16, 2009 / Gene Silencing News - Rosetta, Prometheus Close Deal for miRNA Dx Market Rights
April 30, 2009 / Gene Silencing News - MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis
March 26, 2009 / Gene Silencing News - Strands
February 19, 2009 / Gene Silencing News - Exiqon Exec Says Impact of miRNA Dx Will Take Time, Company Offers Peek at Other Tests
March 5, 2009 / Gene Silencing News